Skip to content


  • Case report
  • Open Access
  • Open Peer Review

Successful treatment of paraneoplastic hypercalcemia in a patient with giant condyloma acuminatum: a case report

  • 1Email author,
  • 1,
  • 2,
  • 3 and
  • 1
Journal of Medical Case Reports20137:251

  • Received: 26 March 2013
  • Accepted: 29 August 2013
  • Published:
Open Peer Review reports



While paraneoplastic syndromes in patients with malignant and metastasizing tumors are common, they are rarely associated with skin tumors showing predominantly local growth patterns. This case report relates to a patient with giant condyloma acuminatum, also called Buschke-Löwenstein tumor, with paraneoplastic hypercalcemia, who was successfully treated with conservative treatment.

Case presentation

The patient in question is a 48-year-old German man with a giant periscrotal tumor. Before and during the therapy, two episodes of symptomatic hypercalcemia occurred, which were successfully treated by bisphosphonates, intravenous fluids and diuretics. No evidence of lytic bone affection was found.


Paraneoplastic hypercalcemia may occur in patients who have a Buschke-Löwenstein tumor. For patients, where surgery is not an option, established medical therapies like bisphosphonates may be useful in addition to diuretics and infusions.


  • Paraneoplastic hypercalcemia
  • Buschke-Löwenstein tumor
  • Giant condyloma acuminatum


Paraneoplastic syndromes occur commonly and are well-known. They may appear before or during tumor manifestation. Different types involving different tissues, for example dermatological, neuronal or endocrinological paraneoplastic syndromes, are known. An incidence up to 10% of paraneoplastic hypercalcemia is reported in patients with lung cancer. It is also commonly seen in aggressive cancers such as breast cancer or multiple myeloma [1]. Paraneoplastic hypercalcemia may appear without evidence of bone metastases [2]. It is the most common metabolism-disorder that is induced by a tumor-associated peptide-releasing hormone [3]. Meyer-Heim et al. assumed a paraneoplastic prevalence in 40% of hypercalcemia [4]. Buschke-Löwenstein tumors are rare and usually grow slowly. They are thought to be induced by the human papilloma virus (HPV), most commonly type 6 and 11 [5]. Usually, it is associated with extensive local infiltration. Most authors consider it to be a verrucous carcinoma, which rarely metastasizes [6].

Case presentation

A 48-year-old German man was admitted with a large scrotal tumor. He had noticed a tumor mass in his right groin 10 years prevoiusly. After a decade of steady state, the tumor was growing rapidly in both his groins and perineum (Figure 1). Our patient was unable to sit because of pain and tumor mass. After a histological examination, a giant condyloma acuminatum was diagnosed. On examination, the patient was in good condition (Karnofsky-Index: 90%, size: 189cm, weight: 75kg). Further examination showed enlarged groin lymph nodes on both sides and a large cauliflower-like, polycyclic scrotal tumor reaching from pubic eminence to anal fissure (width: 20cm, height: 18cm, depth: 25cm). His medical history reported fatigue, but no neuromuscular weakness, polyuria, polydipsia, nausea, vomiting or psychotic phenomena. Arrhythmia was not observed. A supplement of cholecalciferol was not taken. His laboratory results were unremarkable except for a hypercalcemia (Ca2+= 3.64mmol/l). A lower than normal level (LNL) of parathyroid hormone (PTH) and phosphate (parathyroid hormone 9.9 pg/mL, LNL 15 pg/mL; phoshate 2.2mg/dL, LNL 2.7mg/dL) was found (Table 1). His bone scan was normal and a computed tomography scan of his pelvis did not show any evidence for bone affection (Figure 2). Human immunodeficiency virus (HIV) was excluded.
Figure 1
Figure 1

Tumor before starting therapy. This is our first picture showing the tumor mass before starting therapy.

Table 1

Results of the patient’s calcium metabolism

Serum concentration

First stay, first results

First stay, final results

Second stay, first results

Second stay, final results

calcuim (mmol/l)





phosphate (mg/dl)





parathormon (pg/ml)




This table shows the serum calcium levels during the two hospital stays of our patient. Phosphate and parathormon levels were added to show that there was no primary hyperparathyroidism.

Figure 2
Figure 2

Extract of pelvis computed tomography scan showing a destructive, polycyclic growing tumor. This is a picture of a computed tomography scan that we made to exclude bone metastasis. It shows the tumor mass, growing from the anal region (below in the picture) to the groin region (above). Furthermore it shows the local destructive grow-pattern.

A reactive hypoparathyroidism with low phosphate caused by paraneoplastic hypercalcemia was suspected. After a single dose of pamidronate (60mg), saline infusions (3000mL/day) and diuretics (60mg furosemide/day) serum calcium was normalized, and the patient was discharged after six days. In follow-up examinations, slightly elevated calcium levels without clinical significance were detected. Due to the size of the tumor, a combined neoadjuvant therapy which involved radiotherapy of the tumor area up to 45Gy (gray) with a single dose of 1.8Gy plus acitretin was conducted (50mg daily for 43 days). The intensity-modulated radiation therapy technique (IMRT technique) was used. During this therapy, the patient was readmitted with fatigue and elevated calcium levels (3.36mmol/L). His serum phosphate level was normal. Our patient was again treated with a single dose of pamidronate (60mg), infusions and diuretics and discharged three days later. The neoadjuvant treatment resulted in a significant regression of the tumor mass. Pain while sitting had gone and calcium levels remained within normal range. During follow-up examinations (Figure 3) no further episodes of hypercalcemia occured.
Figure 3
Figure 3

Tumor after therapy.


While paraneoplastic hypercalcemia is well-known for many malignant diseases, it is rarely described in patients with localized skin tumors. In a single center study with 412 patients with cutaneous squamous cell carcinoma (SCC), Nicolae et al. reported a low PTH-independent hypercalcemia prevalence of 1.21% [7]. Furthermore, two cases with hypercalcemia-hyperleukocytosis paraneoplastic syndrome in cutaneous squamous cell carcinoma were described [8].

As far as it is known, there is only one case report of paraneoplastic hypercalcemia in Buschke-Löweinstein-tumor [9]. Hernandez et al. described a patient with Buschke-Löwenstein-tumor and elevated PTH-related protein (PTH-rp). After surgical treatment, hypercalcemia was normalized and PTH-rp became undetectable. In this patient, surgery finally resolved the problem. In our patient however, primary surgery was not an option due to the size and mass of the tumor. In the case of paraneoplastic syndrome some authors suggest a three point management plan: involving treatment of the primary tumor to eliminate the source of antigens; steroid based-immunosuppression to avoid antigen-antibody reactions; and symptomatic medication with bisphosphonates, diuretics and infusions to lower elevated calcium levels [10]. In this case, the use of steroids was withheld to await the effect of radiotherapy.


Paraneoplastic hypercalcemia may occur in patients with Buschke-Löwenstein tumor. For patients who are not suitable for surgery, established medical therapies like bisphosphonates may be useful in addition to diuretics and infusions.




We thank our patient for agreeing to present his case.

Authors’ Affiliations

Department of Hematology and Oncology, Academic Teaching Hospital Bielefeld, Teutoburger Str. 50, Bielefeld, 33604, Germany
Department of Surgery and Coloproctology, Academic Teaching Hospital Bielefeld Rosenhöhe, An der Rosenhöhe 27, Bielefeld, 33647, Germany
Department of Radiotherapy, Academic Teaching Hospital Bielefeld, Teutoburger Strasse 50, Bielefeld, 33604, Germany


  1. Clines GA, Guise TA: Hypercalcemia in haematological malignancies and in solid tumors associated with extensive localized bone destruction. Primer on the metabolic bone diseases and disorders of mineral metabolism. Edited by: Favus MJ. 2003, Washington D.C: American Society for Bone and Mineral Research, 251-256. 5Google Scholar
  2. Esbrit P: Hypercalcemia of malignancy--new insights into an old syndrome. Clin Lab. 2001, 47: 67-71.PubMedGoogle Scholar
  3. Horwitz MJ, Stewart AF: Hypercalcemia associated with malignancy. Primer on the metabolic bone diseases and disorders of mineral metabolism. Edited by: Favus MJ. 2006, Washington D.C: American Society of Bone and Mineral Research, 195-199. 6Google Scholar
  4. Meyer-Heim T, Stäubli M: Paraneoplasien. Schweiz Med Forum. 2002, 48: 1139-1145.Google Scholar
  5. Nthumba PM, Ngure P, Nyoro P: Giant condyloma acuminatum of the scrotum in a man with AIDS: a case report. J Med Case Rep. 2011, 5: 272-10.1186/1752-1947-5-272.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Gholam P, Enk A, Hartschuh W: Successful surgical management of giant condyloma accuminatum (Buschke-Löwenstein tumor) in the genitoanal region: a case report and evaluation of current therapies. Dermatology. 2009, 218: 56-59. 10.1159/000165359.View ArticlePubMedGoogle Scholar
  7. Nicolae I, Schipor S: PTH-independent hypercalcaemia and non-melanoma skin cancer. J Eur Acad Dermatol Venereol. 2010, 24: 449-452. 10.1111/j.1468-3083.2009.03441.x.View ArticlePubMedGoogle Scholar
  8. Ben Said B, Maitre S, Perrot JL, Labeille B, Cambazard F: [Hypercalcemia-hyperleukocytosis paraneoplastic syndrome complicating cutaneous squamous cell carcinoma. Report of two cases]. Rev Med Interne. 2010, 31: 309-311. 10.1016/j.revmed.2009.08.004. [Article in French]View ArticlePubMedGoogle Scholar
  9. Hernandez JM, Shibata D: Paraneoplastic hypercalcemia caused by an invasive squamous cell carcinoma arising from a giant anal condyloma acuminatum. Int J Colorectal Dis. 2009, 24: 359-360. 10.1007/s00384-008-0554-5.View ArticlePubMedGoogle Scholar
  10. Krome S: Paraneoplastic syndromes. Dtsch Med Wochenschr. 2012, 137 Suppl 1: S20-S22. doi: 10.1055/s-0032-1301855. Epub 2012 Mar 21 [Article in German]PubMedGoogle Scholar


© Linnemann et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.